February 14, 2018 / 12:18 PM / 11 days ago

Shire ‍posts 16 pct rise in full-year earnings, sees slower growth in 2018

LONDON, Feb 14 (Reuters) - Shire, the pharma firm splitting its rare disease and hyperactivity drugs into two units, said sales would grow in the mid-single digits and profits by a lower percentage than the top line this year after earnings per share rose 16 percent in 2017.

The London-listed company on Wednesday reported full-year revenue of $15.16 billion, up 33 percent, and non-GAAP diluted earnings per ADS of $15.15, which came in towards the top of its guidance.

Reporting by Paul Sandle; editing by James Davey

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below